Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.
Related Articles
Psilocybin May Help Alleviate Cancer-Related Depressive Symptoms
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
A national estimate of mental disorders and mortality outcomes in cancer survivors
The prevalence of various mental disorders and their impact on mortality among cancer survivors were assessed. The results revealed that mental disorders significantly increased the…
Why doesn’t MD Anderson accept Affordable Care Act insurance plans?
MD Anderson does not accept health insurance plans through the Affordable Care Act due…
Heart disease linked to elevated risk for advanced breast cancer
Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have pre-existing cardiovascular disease, according to results of a…
Association of p16(INK4a), a biomarker of cellular senescence, with receipt of therapy and frailty status among adults with plasma cell disorders
Multiple myeloma (MM) accounts for 19 % of hematologic malignancies diagnosed in the United States and has a higher incidence in older adults [1]. Treatment decision-making…
A trial of radiolabeled antibody yttrium‐90–FF‐21101 for the treatment of advanced ovarian and other cancers
A clinical trial of yttrium-90–FF-21101 directed against P-cadherin did not meet predefined efficacy criteria. Because imaging studies indicated FF-21101 uptake by tumors, other warheads combined…
Experts Forecast Cancer Research and Treatment Advances in 2025
Researchers explain how precision medicine, immunotherapy, AI, treating blood cancers, and addressing cancer disparities may advance in 2025.
Endometrial Cancer Advances | Dana-Farber Cancer Institute
A new generation of drugs and drug combinations are improving the outlook for patients with endometrial (uterine) cancer.
NewsDetails
Rachel Darwin, Senior Manager, Public Relations Two-day symposium in Riyadh, Saudi Arabia brings together leading oncology professionals from across the MENA region to review updated…
